• Publications
  • Influence
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel goup, with a median progression- free survival time of 9.2 months (95% CI 8.0-13.9) versus 6.3 months (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<00001). Expand
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy. Expand
Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma
To improve the efficacy of radiofrequency ablation (RFA) for the treatment of intermediate‐sized hepatocellular carcinomas (HCCs), the authors compared RFA combined with transcatheter arterialExpand
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
The encouraging safety and clinical efficacy of nivolumab in patients with platinum-resistant ovarian cancer indicate the merit of additional large-scale investigations (UMIN Clinical Trials Registry UMIN000005714). Expand
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations
Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended. Expand
Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02
The Patient Neurotoxicity Questionnaire has an applicable degree of feasibility and validity, useful for the diagnosis of CIPN as well as for clinical treatment decision-making, where the development of C IPN is a potential treatment-limiting consideration. Expand
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre,
A phase 3 trial to validate the results of the JO25567 study and report here the results from the preplanned interim analysis of the NEJ026 trial, which established the activity and manageable toxicity of erlotinib plus bevacizumab in patients with NSCLC. Expand
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.
Dasatinib discontinuation after sustained deep molecular response for more than 1 year is feasible and rapid molecular responses were seen in all 33 patients, of whom 29 (88%) regainedDeep molecular response within 3 months, as did the remaining four by 6 months. Expand
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
This is the first report indicating that EGFR mutation-positive patients with extremely poor PS benefit from first-line gefitinib, and examination of EGFR mutations as a biomarker is recommended in this patient population. Expand
Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease
The homozygous c.14576G>A variant in RNF213 could be a good DNA biomarker for predicting the severe type of MMD, for which early medical/surgical intervention is recommended, and may provide a better monitoring and prevention strategy. Expand